Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Common Equity (2022 - 2026)

Compass Therapeutics' Common Equity history spans 5 years, with the latest figure at $186.5 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 69.09% to $186.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $186.5 million, a 69.09% increase, with the full-year FY2025 number at $196.8 million, up 57.14% from a year prior.
  • Common Equity hit $186.5 million in Q1 2026 for Compass Therapeutics, down from $196.8 million in the prior quarter.
  • Over the last five years, Common Equity for CMPX hit a ceiling of $209.6 million in Q3 2025 and a floor of $93.2 million in Q2 2025.
  • Historically, Common Equity has averaged $156.9 million across 5 years, with a median of $158.6 million in 2023.
  • Biggest five-year swings in Common Equity: crashed 36.21% in 2025 and later soared 69.09% in 2026.
  • Tracing CMPX's Common Equity over 5 years: stood at $181.6 million in 2022, then decreased by 18.22% to $148.5 million in 2023, then dropped by 15.69% to $125.2 million in 2024, then soared by 57.14% to $196.8 million in 2025, then dropped by 5.24% to $186.5 million in 2026.
  • Business Quant data shows Common Equity for CMPX at $186.5 million in Q1 2026, $196.8 million in Q4 2025, and $209.6 million in Q3 2025.